🇺🇸 FDA
Patent

US 10280423

Compositions and methods for modulating complement factor B expression

granted A61PA61P13/12A61P27/02

Quick answer

US patent 10280423 (Compositions and methods for modulating complement factor B expression) held by Ionis Pharmaceuticals, Inc. expires Mon May 02 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Ionis Pharmaceuticals, Inc.
Grant date
Tue May 07 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 02 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
36
CPC classes
A61P, A61P13/12, A61P27/02, A61P37/02, A61P43/00